##{"id":97010,"date":"2021-10-07T01:00:00","date_gmt":"2021-10-06T14:00:00","guid":{"rendered":"https:\/\/www.fnarena.com\/index.php\/2021\/10\/07\/kazia-therapeutics-to-present-at-ld-micro-main-event\/"},"modified":"2021-10-07T01:00:00","modified_gmt":"2021-10-06T14:00:00","slug":"kazia-therapeutics-to-present-at-ld-micro-main-event","status":"publish","type":"post","link":"https:\/\/staging.fnarena.com\/index.php\/2021\/10\/07\/kazia-therapeutics-to-present-at-ld-micro-main-event\/","title":{"rendered":"Kazia Therapeutics to Present at LD Micro Main Event"},"content":{"rendered":"<p><span class=\"xn-location\">SYDNEY<\/span>, Oct. 6,&#160;2021 \/PRNewswire\/ &#8212; Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr <span class=\"xn-person\">James Garner<\/span>, will be presenting at the LD Micro Main Event, to be held virtually and in person from <span class=\"xn-chron\">12-14 October 2021<\/span>.<\/p>\n<p>Since 2008, the LD Micro Main Event has established itself as one of the leading conferences for small-cap companies across a wide range of sectors. This year&#8217;s event will see approximately 120 participating companies, with presentations over three days. The conference will be conducted in a hybrid format, with a virtual component and an in-person component at the Luxe Sunset Bel Air hotel in <span class=\"xn-location\">Los Angeles, CA.<\/span><\/p>\n<p>Dr Garner&#8217;s presentation will review some of the important developments in Kazia over calendar 2021, which include three cross-border licensing deals and commencement of an international pivotal study for the company&#8217;s lead asset, and will also indicate some of the anticipated developments for the company during the fourth quarter and into calendar 2022.<\/p>\n<p>The Kazia presentation will be available at <span class=\"xn-chron\">10am, ET<\/span>, on <span class=\"xn-chron\">Tuesday, October 12, 2021<\/span> (<span class=\"xn-chron\">1:00am<\/span>, AEDT, on Wednesday, <span class=\"xn-chron\">13 October 2021<\/span>). Registration to the conference is complimentary and can be accessed via the conference website at<span id=\"spanHghltf590\">:<\/span><\/p>\n<p><a target=\"_blank\" href=\"https:\/\/me21.mysequire.com\/\" rel=\"nofollow\">https:\/\/me21.mysequire.com\/<\/a><\/p>\n<p><b>For More Information, Please Contact<span id=\"spanHghltf400\">:<\/span><\/b><\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prntblns\">\n<tbody>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><i><u>In the United States:<\/u><\/i><\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">Joe Green<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">Edison Investor Relations<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\"><a target=\"_blank\" href=\"mailto:jgreen@edisongroup.com\" class=\"prnews_a\" rel=\"nofollow\">jgreen@edisongroup.com<\/a><\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">Phone: +1 646-653-7030<\/span><\/p>\n<\/td>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><i><u>In Australia:<\/u><\/i><\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">Jane Lowe<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">IR Department<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\"><a target=\"_blank\" href=\"mailto:jane.lowe@irdepartment.com.au\" class=\"prnews_a\" rel=\"nofollow\">jane.lowe@irdepartment.com.au<\/a><\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">Phone: +61 411 117 774<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p><b>About Kazia Therapeutics Limited <\/b><\/p>\n<p>Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in <span class=\"xn-location\">Sydney, Australia<\/span>. <\/p>\n<p>Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K \/ Akt \/ mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib commenced recruitment to GBM AGILE, a pivotal study in glioblastoma, in <span class=\"xn-chron\">January 2021<\/span>. Eight additional studies are active in various forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in <span class=\"xn-chron\">February 2018<\/span>, and Fast Track Designation for glioblastoma by the US FDA in <span class=\"xn-chron\">August 2020<\/span>. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in <span class=\"xn-chron\">August 2020<\/span>.<\/p>\n<p>Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in <span class=\"xn-chron\">April 2021<\/span>. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno-oncology agents. A phase I study is expected to begin in CY2021. <\/p>\n<p>For more information, please visit <a target=\"_blank\" href=\"http:\/\/www.kaziatherapeutics.com\/\" rel=\"nofollow\">www.kaziatherapeutics.com<\/a> or follow us on Twitter @KaziaTx.<\/p>\n<p>Related Links :<\/p>\n<p>http:\/\/www.kaziatherapeutics.com<\/p>\n","protected":false},"excerpt":{"rendered":"<p>SYDNEY, Oct. 6,&#160;2021 \/PRNewswire\/ &#8212; Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[105],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts\/97010"}],"collection":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/comments?post=97010"}],"version-history":[{"count":0,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts\/97010\/revisions"}],"wp:attachment":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/media?parent=97010"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/categories?post=97010"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/tags?post=97010"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}